Viking Therapeutics, Inc. (0VQA.L)
USD 39.07
(-17.95%)
USD 39.07
(-17.95%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -54.25 Million USD | -54.72% |
| 2022 | -35.06 Million USD | -33.13% |
| 2021 | -26.34 Million USD | 8.4% |
| 2020 | -28.75 Million USD | -272.75% |
| 2019 | -7.71 Million USD | 68.86% |
| 2018 | -24.77 Million USD | -347.44% |
| 2017 | -5.53 Million USD | -2953.43% |
| 2016 | 194.08 Thousand USD | -85.97% |
| 2015 | 1.38 Million USD | 70.21% |
| 2014 | 812.53 Thousand USD | 719.7% |
| 2013 | 99.12 Thousand USD | 131.87% |
| 2012 | 42.75 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -49.11 Million USD | -14.71% |
| 2024 Q2 | -42.81 Million USD | 77.98% |
| 2024 Q1 | -194.39 Million USD | -258.3% |
| 2023 Q1 | -16.87 Million USD | 51.89% |
| 2023 Q3 | -35.84 Million USD | 47.36% |
| 2023 Q2 | -68.1 Million USD | -303.66% |
| 2023 Q4 | -54.25 Million USD | -51.35% |
| 2023 FY | -54.25 Million USD | -54.72% |
| 2022 Q2 | -14.57 Million USD | -34.77% |
| 2022 Q4 | -35.06 Million USD | -26.27% |
| 2022 Q3 | -27.77 Million USD | -90.56% |
| 2022 FY | -35.06 Million USD | -33.13% |
| 2022 Q1 | -10.81 Million USD | 58.95% |
| 2021 Q2 | -8.63 Million USD | 47.77% |
| 2021 FY | -26.34 Million USD | 8.4% |
| 2021 Q1 | -16.52 Million USD | 42.53% |
| 2021 Q4 | -26.34 Million USD | -136.27% |
| 2021 Q3 | -11.14 Million USD | -29.17% |
| 2020 FY | -28.75 Million USD | -272.75% |
| 2020 Q4 | -28.75 Million USD | -737.94% |
| 2020 Q1 | -14.67 Million USD | -90.17% |
| 2020 Q2 | -18.27 Million USD | -24.56% |
| 2020 Q3 | -3.43 Million USD | 81.22% |
| 2019 Q2 | -18.32 Million USD | -35.98% |
| 2019 Q4 | -7.71 Million USD | 74.47% |
| 2019 Q3 | -30.21 Million USD | -64.93% |
| 2019 Q1 | -13.47 Million USD | 45.62% |
| 2019 FY | -7.71 Million USD | 68.86% |
| 2018 Q1 | -32.63 Million USD | -489.3% |
| 2018 FY | -24.77 Million USD | -347.44% |
| 2018 Q4 | -24.77 Million USD | 85.38% |
| 2018 Q3 | -169.5 Million USD | -389.76% |
| 2018 Q2 | -34.61 Million USD | -6.05% |
| 2017 Q4 | -5.53 Million USD | -1004.38% |
| 2017 Q3 | 612.34 Thousand USD | 278.41% |
| 2017 Q2 | -343.22 Thousand USD | 46.87% |
| 2017 Q1 | -646.01 Thousand USD | -432.86% |
| 2017 FY | -5.53 Million USD | -2953.43% |
| 2016 Q1 | -818.9 Thousand USD | -159.21% |
| 2016 Q4 | 194.08 Thousand USD | 184.84% |
| 2016 Q3 | -228.75 Thousand USD | 91.76% |
| 2016 Q2 | -2.77 Million USD | -239.14% |
| 2016 FY | 194.08 Thousand USD | -85.97% |
| 2015 Q1 | 1.41 Million USD | 73.94% |
| 2015 Q2 | -7.82 Million USD | -653.77% |
| 2015 Q3 | -229.09 Thousand USD | 97.07% |
| 2015 Q4 | 1.38 Million USD | 703.69% |
| 2015 FY | 1.38 Million USD | 70.21% |
| 2014 Q1 | 206.27 Thousand USD | 108.09% |
| 2014 Q2 | -279.72 Thousand USD | -235.61% |
| 2014 FY | 812.53 Thousand USD | 719.7% |
| 2014 Q4 | 812.53 Thousand USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | 99.12 Thousand USD | 0.0% |
| 2013 Q3 | 99.12 Thousand USD | 0.0% |
| 2013 FY | 99.12 Thousand USD | 131.87% |
| 2012 FY | 42.75 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | -87.11 Million USD | 37.72% |
| Dynavax Technologies Corporation | 106.63 Million USD | 150.88% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | -61.828% |
| Perrigo Company plc | 3.32 Billion USD | 101.633% |
| Illumina, Inc. | 1.21 Billion USD | 104.469% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 100.202% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 52.36% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 100.659% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 100.422% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 137.398% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | -100.207% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 854.919% |
| Waters Corporation | 1.96 Billion USD | 102.768% |
| Biogen Inc. | 6.28 Billion USD | 100.863% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -664.169% |
| Evolus, Inc. | 63.7 Million USD | 185.164% |
| Adicet Bio, Inc. | -142 Million USD | 61.794% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -501.775% |
| bluebird bio, Inc. | 108.57 Million USD | 149.973% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 111.828% |
| FibroGen, Inc. | 56.76 Million USD | 195.577% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 104.739% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 878.637% |
| Homology Medicines, Inc. | 18.43 Million USD | 394.278% |
| Geron Corporation | 14.76 Million USD | 467.563% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 103.422% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 127.393% |
| Myriad Genetics, Inc. | 88.1 Million USD | 161.585% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 51.297% |
| Zoetis Inc. | 4.76 Billion USD | 101.139% |
| Abeona Therapeutics Inc. | -10.07 Million USD | -438.735% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 102.586% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 114.325% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.433% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -272.33% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 105.146% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 270.162% |
| Verastem, Inc. | -37.27 Million USD | -45.544% |
| Nektar Therapeutics | 210.24 Million USD | 125.807% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 72.848% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | -47.419% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 105.603% |
| OPKO Health, Inc. | 230.68 Million USD | 123.52% |
| Exelixis, Inc. | -73.05 Million USD | 25.728% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 130.601% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 59.929% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 64.075% |
| uniQure N.V. | -102.95 Million USD | 47.299% |
| Imunon, Inc. | -4.69 Million USD | -1054.562% |
| Blueprint Medicines Corporation | 702.83 Million USD | 107.72% |
| Insmed Incorporated | 721.62 Million USD | 107.519% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 103.929% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | -73.803% |
| TG Therapeutics, Inc. | 17.86 Million USD | 403.751% |
| Incyte Corporation | -3.17 Billion USD | 98.291% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 107.085% |